-
Sector Analysis
![]()
PharmaPoint: Melanoma – Global Drug Forecast and Market Analysis to 2026
Melanoma is the deadliest and most aggressive form of skin cancer. Melanoma is rare compared with other major cancer indications, but the incident cases are increasing because of the aging population and changes in lifestyle that result in more ultraviolet (UV) exposure. Since 2011, the FDA/EMA have approved four immunotherapies, starting with the CTLA-4 targeting mAb, Yervoy (ipilimumab, Bristol-Myers Squibb), followed by PD-1 targeting mAbs, Keytruda (pembrolizumab, Merck & Co) and Opdivo (nivolumab, Ono/Bristol-Myers Squibb) and finally, oncolytic viral therapy,...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.